Merck U.S. Human Health management
Executive Summary
Merck/Schering Pharmaceuticals General Manager Adam Schechter will succeed Brad Sheares as president of Merck's U.S. Human Health division, effective immediately. In his position heading the Merck/Schering-Plough joint venture, Schechter oversaw initiatives such as the launch of the ezetimibe/simvastatin fixed-dose combination Vytorin in 2004. Sheares, a nearly 20-year veteran of Merck, was appointed president of USHH in 2001 and was seen as one potential successor to CEO Richard Clarke (1"The Pink Sheet" May 9, 2005, p. 14). It is understood that President-Human Health Intercontinental Per Wold-Olsen, also once seen as a possible Clarke successor, has left the company as well...